



**PBS-listed for type 2 diabetes** as add-on therapy; favoured with established CVD or CKD. Initiation gate: contraindication/intolerance to an SGLT2 inhibitor, or no clinically meaningful glycaemic response to one. Verify current criteria at [pbs.gov.au](https://pbs.gov.au).

## ELIGIBILITY — WHO QUALIFIES ON THE PBS

- ✓ **Diagnosis** Type 2 diabetes mellitus — not type 1, LADA, MODY or gestational diabetes.
- ✓ **SGLT2i criterion** Contraindication/intolerance requiring discontinuation of an SGLT2 inhibitor, or no clinically meaningful glycaemic response to one. This is the current initiation gate (PBAC, June 2024).
- ✓ **Combination** Used with at least one of metformin, a sulfonylurea or insulin — see the combinations table below.
- ✓ **Authority** Initiation: Authority Required — phone 1800 888 333 or PBS Online / HPOS. Continuation: Streamlined (no phone call).

## WHICH COMBINATIONS ARE PBS-SUBSIDISED

Combination with	Subsidised?	Notes
+ Metformin	Yes	Dual therapy.
+ Sulfonylurea	Yes	Dual therapy.
+ Metformin + SU	Yes	Triple therapy.
+ Insulin	Yes	Dual or triple therapy, with or without metformin.
+ SGLT2i / DPP-4i	No	Not co-subsidised for diabetes. SGLT2i exception: prescribed for HF/CKD with no glycaemic response. Never with another GLP-1 RA.

## PRACTICAL PRESCRIBING

- Not available on 60-day prescriptions (GLP-1 RAs and insulins are excluded) — 30-day quantities only. The 1.5 mL pen was discontinued; the 3 mL pen is the current presentation (same dose delivered).
- Patients already established on a GLP-1 RA for T2DM do not need to requalify under the 2024 rules.
- Ozempic is the T2DM stream; Wegovy (obesity / CV-risk) is a separate, locked indication — patients cannot switch streams to bypass criteria. Confirm strengths, pack sizes and repeats at [pbs.gov.au](https://pbs.gov.au).

### ■ SAFETY

- Not for type 1 diabetes, LADA or DKA
- MEN2 / medullary thyroid cancer (personal or family history)
- Acute pancreatitis — withhold; specialist before any restart
- Cease ≥ 2 months before a planned pregnancy

### ◆ CHECK / EXCLUDE

- Confirm and document the SGLT2i criterion before initiating
- Not with a DPP-4i, another GLP-1 RA or an SGLT2i for diabetes
- Hypoglycaemia risk rises with insulin or a sulfonylurea
- Re-verify the current PBS restriction at [pbs.gov.au](https://pbs.gov.au)